Research Analysts Set Expectations for VRTX FY2026 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Zacks Research upped their FY2026 EPS estimates for shares of Vertex Pharmaceuticals in a report released on Wednesday, April 9th. Zacks Research analyst R. Department now expects that the pharmaceutical company will earn $16.34 per share for the year, up from their previous estimate of $16.18. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q4 2026 earnings at $4.44 EPS and FY2027 earnings at $18.02 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%.

Several other equities analysts also recently commented on the stock. Barclays upped their price target on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Bank of America upped their price objective on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a research report on Monday, March 31st. Stifel Nicolaus lifted their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. Finally, StockNews.com upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 11th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $512.41.

Vertex Pharmaceuticals Stock Up 2.4 %

NASDAQ VRTX opened at $495.83 on Monday. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The firm has a market capitalization of $127.32 billion, a price-to-earnings ratio of -225.38, a PEG ratio of 2.11 and a beta of 0.50. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $484.98 and a two-hundred day moving average of $464.51.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares of the company’s stock, valued at $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Ourania Tatsis sold 244 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares in the company, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock valued at $2,121,012 in the last ninety days. Corporate insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 19.2% during the 1st quarter. Farther Finance Advisors LLC now owns 2,871 shares of the pharmaceutical company’s stock worth $1,392,000 after acquiring an additional 462 shares in the last quarter. Daymark Wealth Partners LLC purchased a new position in Vertex Pharmaceuticals during the first quarter worth approximately $226,000. Portside Wealth Group LLC grew its holdings in Vertex Pharmaceuticals by 30.0% in the first quarter. Portside Wealth Group LLC now owns 2,945 shares of the pharmaceutical company’s stock valued at $1,428,000 after purchasing an additional 679 shares during the period. Moss Adams Wealth Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 62.5% in the first quarter. Moss Adams Wealth Advisors LLC now owns 863 shares of the pharmaceutical company’s stock valued at $419,000 after buying an additional 332 shares in the last quarter. Finally, Capital Investment Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 22.6% during the 1st quarter. Capital Investment Advisors LLC now owns 1,032 shares of the pharmaceutical company’s stock worth $500,000 after buying an additional 190 shares during the period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.